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Abstract: Cyclic Arg-Gly-Asp-D-Phe-Lys [c(RGDfK)] targeted poly(L-glutamic acid) (PGA)-
(Gd-DO3A) conjugate with a biodegradable cystamine spacer was prepared and evaluated for 
in vivo detection of an angiogenesis biomarker, ανβ3 integrin, in neoplastic tissues with T1 
mapping, a quantitative magnetic resonance imaging (MRI) technique. The binding activity 
of the c(RGDfK) containing conjugate was investigated using in vitro vitronectin assay with 
human prostate carcinoma DU145 cell line and Kaposi’s sarcoma SLK cell line. The peptide 
c(RGDfK) and PGA-cystamine-(Gd-DO3A) conjugate were used as controls. The binding af-
ﬁ  nity of polymer bound c(RGDfK) was slightly lower than free c(RGDfK) peptide. The RGD 
targeted conjugate had higher binding afﬁ  nity to the DU145 cells than the SLK cells, which 
was consistent to free c(RGDfK). The imaging of ανβ3 integrin with targeted PGA-cystamine-
(Gd-DO3A) was evaluated in nude mice bearing DU145 and SLK xenografts at a dose of 5 
μmol-Gd/kg. The targeted conjugate demonstrated higher in vivo binding afﬁ  nity to the DU145 
xenografts than the SLK xenografts, resulting in a signiﬁ  cant decrease of T1 values of water 
protons in the periphery of the DU145 tumors as shown in the MR T1 maps. No signiﬁ  cant 
decrease of T1 values was observed in the SLK tumor with the targeted conjugate and in both 
tumors with the non-targeted conjugate. The targeted polymeric Gd(III) chelate conjugate with 
a degradable spacer has the potential to be a new paradigm for safe and effective probes in 
molecular imaging with quantitative MR T1 mapping. 
Keywords: MRI contrast agent, ανβ3 integrin, RGD, PGA-cystamine-(Gd-DO3A), MR T1 
mapping
Introduction 
Excessive angiogenesis is involved in tumor proliferation and many other disorders. 
Noninvasive speciﬁ  c imaging of angiogenesis is critical for more accurate and earlier 
detection of angiogenic diseases and the assessment of antiangiogenic therapeutic 
efﬁ  cacy. The ανβ3 integrin is one of several proteins involved in the angiogenic process 
and is a potent biomarker for angiogenesis. The ανβ3 integrin is highly expressed at the 
surface of proliferating endothelial cells in neoplastic and metastatic tissues (Brooks 
et al 1994). It is a viable molecular target for detecting angiogenesis and evaluating 
the efﬁ  cacy of antiangiogenesis treatment (Haubner et al 2001; Achilefu et al 2005; 
Line et al 2005; Schmieder et al 2005). Contrast enhanced magnetic resonance imag-
ing (MRI) can be effective for molecular imaging of the ανβ3 integrin if a sufﬁ  cient 
amount of contrast agent is delivered to the target (Sipkins et al 1998).
Previously, we have conjugated Gd-DO3A to biocompatible poly(L-glutamic acid) 
(PGA) via a cleavable cystamine spacer to develop a safe and effective macromolecular 
MRI contrast agent (Lu et al 2003; Ke et al 2006). A large amount of Gd-DO3A chelates 
can be loaded onto the polymeric carrier. The degradable disulﬁ  de spacer can be International Journal of Nanomedicine 2007:2(2) 192
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reduced by endogenous free thiols (eg, cysteine and reduced 
glutathione) to facilitate the excretion and to minimize the 
long-term body accumulation of toxic Gd(III) ions after the 
MRI study. Incorporation of an ανβ3 integrin speciﬁ  c targeting 
moiety to the polymer conjugate can result in a targeted 
macromolecular MRI contrast agent for in vivo detection of 
the biomarker with MRI.
We report here the synthesis and evaluation of an Arg-
Gly-Asp (RGD) targeted PGA-cystamine-(Gd-DO3A) conjugate 
for in vivo detection of the ανβ3 integrin in neoplastic tissues with 
MR T1 mapping. RGD is a peptide motif that can speciﬁ  cally 
bind to the ανβ3 integrin (Pasqualini et al 1997). T1 mapping is 
a quantitative MRI technique and can accurately measure and 
map the T1 values of water protons in organs and tissues. When 
the targeted polymer conjugate binds to the molecular target, 
it decreases the T1 values of surrounding water protons. The 
overexpressed ανβ3 integrin can be visualized in the MR T1 map 
where the T1 values decrease signiﬁ  cantly due to the binding of 
the targeted contrast agent.
Materials and methods 
Poly(L-glutamic acid) (PGA) (Mw = 80.8 KDa, Mn = 69.1 KDa) 
was synthesized according to the literature (Idelson and Blout 
1958). Mono-Boc-cystamine (Lu et al 2003) and N-suc-
cinimidyl bromoacetate (Callahan et al 1989) were prepared 
according to literature methods. Di-tert-butyl dicarbonate and 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) were purchased from Nova Chemicals (La Jolla, CA). 
1,4,7,10-Tetraazacyclododecane (cyclen) was purchased from 
Macrocyclics (Dallas, TX). 1,4,7,10-Tetraazacyclododec-
ane-1,4,7-trisacetic acid (DO3A) was synthesized according 
to a published method (Ke et al 2006). Bromoacetic acid, 
N-hydroxysuccinimide (NHS) and N-diisopropylethylamine 
(DIEA) were purchased from Lancaster Synthesis, Inc. (Pelham, 
NH). Gadolinium(III) acetate and tert-butyl bromoacetate were 
purchased from Alfa Aesar (Ward Hill, MA). Ethylenediami-
netetraacetic acid (EDTA) dipotassium salt and cystamine 
dichloride were purchased from Sigma-Aldrich (St. Louis, MO). 
The peptide of cyclo{Arg-Gly-Asp-D-Phe-(ω-N-(N-(8-amino-3,
6-dioxaoctanoyl)-8-amino-3,6-dioxaoctanoyl)Lys)} was cus-
tom-made by Peptides International, Inc. (Louisville, KY). All 
chemicals were used without further puriﬁ  cation. Spectra/Por® 
6 membrane (MWCO: 25,000) was purchased from Spectrum 
Laboratory, Inc. (Rancho Dominguez, CA). Matrigel was 
purchased from BD Biosciences (San Jose, CA). Human prostate 
carcinoma DU145 cell line and Kaposi’s sarcoma tumor SLK 
cell line were purchased from the ATCC collection (Manassas, 
VA, USA) and cultured in ﬂ  asks in Modiﬁ  ed Eagle’s Minimum 
Essential medium (MEM) with 10% fetal bovine serum for 
DU145 cells and RPMI 1640 medium with 10% fetal calf serum 
for SLK cells. 
NMR spectra were recorded at 25 °C on a varian INOVA 
400 at 400MHz. ESI mass spectra were acquired on PE Sciex 
API III Mass Spectrometer. The molecular weights of the 
polymers were determined by size exclusion chromatogra-
phy (SEC) on an AKTA FPLC system with a Superose 6 
column equipped with UV and refractive index detectors 
(calibrated with poly[(N-2-hydroxypropyl)methacrylamide] 
standards). The Gd content in the conjugates was determined 
by inductively coupled plasma-optical emission spectroscopy 
(ICP-OES, Perkin-Elmer, Optima 3100XL, Norwalk, CT). 
Amino acid analysis was done on Beckmann 6300 ninhydrin-
based system. 
Synthesis of N-t-Boc-cystamine 
bromoacetamide
N-Succinimidyl bromoacetate (2.83 g, 12 mmol) was added 
to a solution of mono-N-t-Boc-cystamine (2.25 g, 10 mmol) 
in methylene chloride (50 ml) at 0 °C and the mixture was 
stirred overnight at room temperature. The reaction solution 
was washed with 1 M NaHSO4 solution (3 × 30 ml) and dried 
over anhydrous MgSO4. The product was isolated by ﬂ  ash 
chromatography with 3:1 hexane/ethyl acetate. Yield: 2.36 g 
(71%). 1HNMR, δH (CDCl3, ppm): 7.14 (1H, br, NHCO of 
bromoacetamide), 4.95 (1H, br, NHCO of Boc), 3.87 (2H, 
s, CH2Br), 3.59 (2H, t, CH2N near to bromoacetamide), 3.44 
(2H, t, CH2N near to Boc), 2.83 (2H, t, CH2S near to bro-
moacetamide), 2.77 (2H, t, CH2S near to Boc), 1.42 (9H, s, 
(CH3)3C–). ESI-MS (m/z, M+H+): 373.1 (measured), 373.0 
(calculated).
Synthesis of 1,4,7,10-
tetraazacyclododecane-1,4,7-tris
(acetic acid)-10-(acetic acid-cystamine 
monoamide) (I) 
DO3A (0.7 g, 1.5 mmol) and N-Boc-cystamine bromo-
actamide (1.05 g, 3.0 mmol) were dissolved in a mixture of 
14 mL methanol and 7 mL triethylamine. An excess of anhy-
drous K2CO3 was added to the solution. The reaction mixture 
was stirred overnight at room temperature and the solvent 
was then removed under vacuum. The residue was washed 
with ether and acetone, and then dissolved in 5 mL cold water 
in an ice bath. The solution was acidiﬁ  ed to pH = 2~3 with 
1N HCl, then concentrated to dryness under vacuum. The 
residue was washed using ether and acetone, and the product International Journal of Nanomedicine 2007:2(2) 193
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was extracted from the solid residue with a mixed solvent of 
14 mL methanol and 7 mL triethylamine. After the solvent 
was evaporated under vacuum, the residue was dissolved 
in 3 mL triﬂ  uoroacetic acid in ice bath and stirred for 15 
minutes at room temperature to remove the Boc protection. 
Triﬂ  uoroacetic acid was evaporated under vacuum and the 
residue was washed with ether. The ﬁ  nal product, a white 
solid, was collected and dried under vacuum. Yield: 0.91 g 
(60%). 1HNMR, δH (D2O, ppm): 3.34–3.69 (8H, m, CH2CO 
of acetic acid and acetamide), 3.16–3.34 (4H, m, CH2N of 
cystamine), 2.90–3.15 (16H, m, CH2N of cyclen), 2.70–2.90 
(4H, m, CH2S of cystamine). ESI-MS (m/z, M+H+): 539.3 
(measured), 539.2 (calculated).
Synthesis of PGA-OSu ester
PGA (500 mg) and N-hydroxysuccinimide (2.5 g, excess) 
were dissolved in 20 mL anhydrous DMF. EDC (2.5 g) was 
then added to the solution. The reaction mixture was stirred 
for 3 days at room temperature, and then concentrated under 
vacuum. The residue was dropped into 30 mL anhydrous 
acetone to precipitate PGA-OSu active ester. The polymer was 
collected by ﬁ  ltration, washed with acetone and dried under 
vacuum. Yield: 867 mg (100%). 1HNMR, δH (d6-DMSO, 
ppm): 8.25 (1H, br, NHCO), 4.18 (1H, br, NHCHCO), 
2.40–3.20 (6H, m, CH2CO), 2.08 (2H, br, CH2).
Synthesis of PGA-cystamine-
[Gd(III)-DO3A]-c(RGDfK) conjugate
PGA-OSu (40 mg), c(RGDfK) (30 mg, 0.026 mmol), and 
p-dimethylaminopyridine (216 mg, 1.77 mmol) were dis-
solved in 6 mL anhydrous DMF. The mixture was stirred for 
2 h at room temperature and then compound I (212 mg, 0.21 
mmol) was added into solution. The reaction mixture was 
stirred to react for 24 h at room temperature. The solution was 
then diluted with water in an ice bath and dialyzed against 
deionized water with Spectrra/Por® 6 membrane (molecular 
weight cutoff: 25,000 Da, Spectrum Laboratory, Inc). The 
polymeric ligand was then reacted with an excess of Gd(OAc)3 
(100 mg) overnight at room temperature in aqueous solution 
at pH 6. Xylenol orange indicator was then added, followed 
by EDTA until the pink color disappeared. The paramagnetic 
conjugate was puriﬁ  ed by dialysis with Spectra/Por® 6 mem-
brane and lyophilized. Yield: 42 mg (62%). The gadolinium 
content in the conjugate was 27 mol-%, as determined by ICP-
OES. The content of c(RGDfK) was 13 mol-% by amino acid 
analysis, determined by the ratio of normalized concentration 
of D-phenylalanine to glutamic acid.
Synthesis of PGA-cystamine-
[Gd(III)-DO3A]
PGA-cystamine-[Gd(III)-DO3A] was similarly prepared 
according to above described method without c(RGDfK). 
Yield: 70%. The gadolinium content was 20.8 mol-%, as 
determined by ICP-OES. 
T1 relaxivity measurement
T1 relaxation times for the polymeric contrast agents of three 
concentrations and water were determined by sequential 
application of a standard inversion-recovery (IR) pulse 
sequence on a Siemen Trio 3T scanner. The parameters were 
5000 ms repetition time (TR), 17 ms echo time (TE) and, 22, 
25, 30, 35, 40, 50, 100, 200, 300, 400, 500, 600, 700, and 
800 ms inversion time (TI). Net magnetization amplitude 
data for each sample were measured at regions of interest. T1 
and M0 were calculated by ﬁ  tting the Marquardt-Levenberg 
algorithm with multiparametric nonlinear regression (Liang 
and Lauterbur 2000; Mohs et al 2005). The relaxivity r1 was 
calculated from the slop of the plot of 1/T1 vs [Gd (III)].
Binding assay of the conjugates
The binding activity of the c(RGDfK) in the targeted 
polymeric contrast agent was studied in an ανβ3 integrin 
dependent adhesion assay according to a reported method 
(Kok et al 2002; Schmieder et al 2005). Brieﬂ  y, ﬂ  at bottom 
96-well culture plates were coated overnight with vitronec-
tin (500 ng/well in PBS) at 4 °C. After washing with PBS, 
the wells were incubated with 1% bovine serum albumin 
(BSA) for 2 h at 37 °C to block nonspeciﬁ  c binding and 
washed two times with PBS. The DU 145 and SLK cells 
were trypsinized and resuspended in serum free MEM at 
a concentration of 2 × 105 cells/mL. Aliquots (100 μL) of 
cell suspensions and serum free MEM (blank) or solutions 
of c(RGDfK), PGA-cystamine-(Gd-DO3A)-c(RGDfK) and 
PGA-cystamine-(Gd-DO3A) were mixed and incubated 
for 15 min at 4 °C. The concentrations of c(RGDfK) were 
5 μM or 50 μM for both c(RGDfK) and PGA-cystamine-(Gd-
DO3A)-c(RGDfK). The concentration of PGA-cystamine-
(Gd-DO3A) was the same as PGA-cystamine-(Gd-DO3A)-
c(RGDfK) based on the Gd content. The mixtures were 
then plated at 2 × 104 cells/well (200 μL) and allowed 
to adhere for 24 h at 37 °C. The unattached cells were 
removed from the wells by washing ﬁ  ve times with PBS. 
The attached cells were ﬁ  xed with 3.7% paraformaldehyde 
for 30 minutes at room temperature, washed twice with 
PBS and stained with 0.1% crystal violet (50 μL/well) at International Journal of Nanomedicine 2007:2(2) 194
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25 °C for 30 min. Excess dye was removed by washing with 
deionized water and 0.2% Triton-X (50 μL/well) was added 
to extract dye absorbed by adherent cells. Absorbance was 
measured at 575 nm on a Molecular Devices Spectra Max 
M2 microplate reader (Sunnyvale, CA). The results were 
normalized to the control.
Animal tumor model
Male athymic nude mice (25–30 grams, 8 weeks old, Animal 
Production Program of National Cancer Institute at Frederick, 
Frederick, MD) were cared under the guidelines of an 
approved protocol from the University of Utah Institutional 
Animal Care and Use Committee. A suspension of DU 145 
cells in the MEM or SLK cells in the RPMI-1640 medium at 
2 × 107 cells/mL was mixed with an equal volume of Matrigel 
(Becton-Dikinson, Franklin Lakes, NJ). The Matrigel mix-
tures of DU145 cells and SLK cells (2 × 106 cells in 200 μL) 
were subcutaneously implanted into the upper left and right 
ﬂ  anks of the mice, respectively. Tumors in both ﬂ  anks 
reached 0.5–1.5 cm in diameter three weeks post-inoculation 
and were ready for experiment.
Dynamic T1 mapping
Mice bearing tumor xenografts were anesthetized by intra-
peritoneal administration of a mixture of ketamine (45 mg/kg) 
and xylazine (6 mg/kg). The contrast agents were injected via 
a tail vein at a dose of 5.0 μmol-Gd/kg. A group of three mice 
was used for each conjugate. The MRI data were acquired 
on a Siemens Trio 3T MRI system (Siemens Medical Solu-
tion, Erlangen, Germany). High-resolution MR images of the 
mice was acquired before and 8 minutes after the injection of 
contrast agents using a 3D FLASH sequence with 0.5 mm3 
isotropic resolution, 128 × 64 × 48 imaging matrix, 7.5 ms 
TR, 2.7 ms TE, and 4 signal averages. The imaging time was 
1 min 30 sec. T1 mapping source images were acquired using 
a spoiled gradient-echo pulse sequence with 128 × 64 imaging 
matrix, 300 ms TR, 1.75 ms TE, and ﬂ  ip angles 10, 20, 30 
and 45º. The in-plane resolution was 1.0 × 1.0 mm2 with 2.0 
mm slice thickness. Data acquisition duration for each ﬂ  ip 
angle and 8 slices was 15 sec. Since T1 mapping with ﬂ  ip 
angle variations is very sensitive to the RF ﬁ  eld variation, 
mouse was positioned with tumor tissues located near the 
center of the RF coil. The dynamic images for T1 mapping 
were processed pixel-by-pixel for all time points by custom 
software using IDL (Interactive Data Language, Boulder, 
CO) to construct the T1 maps. For calculating the longitudinal 
relaxation time T1, the signal intensities were ﬁ  tted according 
to the following equation (Deoni et al 2003):
where Ee S r T R
TR T r
1 1
1 =−
− () ; ( ; , )
/( )
 
α  is the measured signal 
intensity for a ﬂ  ip angle with the ﬁ  xed TR, at the position.
Statistical analysis
Statistical analysis was performed using the t-test (GraphPad 
Prism; GraphPad Software, San Diego, CA). P values were 
two-tailed with a conﬁ  dence interval of 95%. Difference was 
considered signiﬁ  cant when p < 0.05.
Results
The RGD targeted poly(L-glutamic acid)-(Gd-DO3A) 
conjugate was synthesized by stepwise conjugation of 
DO3A cystamine monoamide (I) and a pentameric cyclic 
peptide c(Arg-Gly-Asp-D-Phe-Lys) [c(RGDfK), II] to poly-
(L-glutamic acid) N-hydroxysuccinimide ester (PGA-NHS), 
followed by complexation with Gd(OAc)3, Scheme 1. The 
c(RGDfK) peptide was ﬁ  rst conjugated to PGA via a long 
spacer N-(8-amino-3,6-dioxaoctanoyl)-8-amino-3,6-dioxa-
octanoic acid (ADAD), which was designed to minimize the 
steric hindrance of the polymer chain for RGD to bind with 
its target. EDTA was used to remove the excess Gd(III) ions 
bound to the carboxylic groups of PGA. PGA-cystamine-
(Gd-DO3A) conjugate was similarly prepared as a control 
agent. The physicochemical parameters of two conjugates are 
listed in Table 1. The content of c(RGDfK) in the targeted 
conjugate was approximately 13 mol-%, as determined by 1H 
NMR spectrometry before Gd complexation and by amino 
acid analysis after complexation. The gadolinium content 
was approximately 27 mol-%, as determined by ICP-OES. 
The T1 relaxivity of the targeted and non-targeted conjugates 
was 9.7 and 8.2 mM-1s-1 per complexed Gd(III) ion at 
3 Tesla, respectively. The apparent molecular weights of the 
conjugates were different from those of the starting polymers 
because of the decrease in hydrodynamic volumes of the 
polymers after conjugation.
Table1 Physical chemical parameters of PGA-cystamine-(Gd-
DO3A) and PGA-cystamine-(Gd-DO3A )-c(RGDfK) conjugates
Property PGA-cystamine-  PGA-cystamine-
 (Gd-DO3A)  (Gd-DO3A)-c(RGDfK)
Mw (KDa)  79.3  49
Mw/Mn 1.81  1.89
Gd content, (w/w)%b 12.14  9.27
Molar conjugation ratio  20.8  27
R1 (mM-1s-1) 7.8  9.7
Sr T R
E
Sr T R
ME
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The binding activity of the c(RGDfK) containing con-
jugate was investigated by an in vitro vitronectin assay 
with the human prostate carcinoma DU145 cell line and 
Kaposi’s sarcoma SLK cell line. The c(RGDfK) peptide 
and PGA-cystamine-(Gd-DO3A) conjugate were used as 
controls. The ανβ3 integrin is expressed on the surface of 
both DU145 (Romanov and Goligorsky 1999) and SLK 
cells (Samaniego et al 2002). Figure 1 shows the inhibition 
of cell attachment to vitronectin–coated plates by the agents. 
Both c(RGDfK) and the c(RGDfK) containing conjugate 
exhibited stronger concentration-dependent inhibition for 
the DU145 cells than the SLK cells. The percentages of cell 
attachment for free c(RGDfK) and conjugated c(RGDfK) 
at 50 μM were 3.4 ± 3.8% (p < 0.01 when compared with 
the control) and 14 ± 4.9% (p < 0.01) for the DU145 cells, 
and 25 ± 17.4% (p < 0.01) and 56 ± 9% (p < 0.01) for the 
SLK cells, respectively. The percentages of cell attachment 
for free c(RGDfK) and conjugated c(RGDfK) at 5 μM were 
34 ± 8.2% (p < 0.01) and 53 ± 5% (p < 0.01) for the DU145 
cells, and 54 ± 6.5 (p < 0.05) and 67 ± 20.3% (p = 0.15) for 
the SLK cells, respectively. The non-targeted conjugate did 
not have signiﬁ  cant effect on cellular adherence inhibition 
(p > 0.05) for both cell lines at both 5 and 50 μM. The results 
showed the c(RGDfK) in the conjugate maintained the af-
ﬁ  nity to the ανβ3 integrin after conjugation.
Figure 2 shows the coronal MR images of tumor bearing 
mice before and at 8 minutes after injection of the conju-
gates at a dose of 5 μmol-Gd/kg. The low dose was used to 
effectively evaluate the targeting efﬁ  ciency by minimizing 
non-speciﬁ  c accumulation of the polymeric agents in tumor 
tissues. Both conjugates resulted in signal enhancement in the 
liver and blood. No signiﬁ  cant enhancement was observed in 
both DU145 and sarcoma tumors for the targeted conjugate 
and control conjugate. Conventional MRI was not sensitive 
enough to detect the binding of the targeted contrast agent 
in the tumor tissue.
Figure 3 shows color-coded T1 maps before and at 9.5 and 
17.5 minutes after the injection of the contrast agents. The maps 
show that the tumor tissues had relatively higher T1 values as 
compared to the surrounding tissue. The targeted conjugate 
resulted in a signiﬁ  cant decrease of   T1 values at the tumor 
periphery of the DU145 xenografts, which had a high binding 
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activity to the targeted conjugate. No signiﬁ  cant change of the 
T1 values was found in DU-145 tumor with the non-targeted 
agent and the SLK tumor for both conjugates. Quantitative T1 
measurement was more sensitive to detect the binding of the tar-
geted conjugate in different tumors than conventional MRI.
Discussion
Magnetic resonance imaging is less sensitive for molecular 
imaging than nuclear medicine. A relatively large amount of 
Gd(III) chelates is required in order to generate detectable 
signals to visualize molecular targets. Biocompatible 
polymeric conjugates are effective drug delivery systems for 
both therapeutics and diagnostics. A large amount of Gd(III) 
chelates can be loaded onto the conjugates, and targeting 
agents can also be incorporated to develop targeted MRI 
contrast agents. The biodegradable disulﬁ  de spacer allows 
release of Gd(III) chelates from the conjugates, facilitating 
rapid excretion of the Gd(III) chelates after the imaging 
studies (Wang et al 2005; Feng et al 2006). Rapid excretion 
and minimal retention of Gd(III) chelates are critical for 
clinical application of the targeted polymer paramagnetic 
conjugates. Targeted polymeric Gd(III) chelate conjugates 
DU145
0
20
40
60
80
100
120
140
Control RGD* RGDP* P*
*
*
*
*
SLK
0
20
40
60
80
100
120
140
Control RGD* RGDP P*
*
*
*
C
e
l
l
 
A
t
t
a
c
h
m
e
n
t
 
(
%
)
C
e
l
l
 
A
t
t
a
c
h
m
e
n
t
 
(
%
)
Figure 1 Percentage of cell attachment of human prostate carcinoma DU145 cells and Kaposi’s sarcoma SLK cells to the vitronectin-coated plates inhibited by MEM serum 
free media (control) or solutions of c(RGDfK) (RGD), c(RGDfK) containing PGA-cystamine-(Gd-DO3A) (RGDP), and PGA-cystamine-(Gd-DO3A) (P) at the concentra-
tions of 5 μM (closed bar) and 50 μM (open bar). Values are shown as means ± SD (n = 5). The “*” symbol indicates p < 0.05. The comparison is made to the control. International Journal of Nanomedicine 2007:2(2) 197
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with a biodegradable spacer have a potential for in vivo 
molecular imaging with MRI.
The RGD targeted PGA-cystamine-(Gd-DO3A) conju-
gate had a relatively high load of Gd(III) chelates. A high 
RGD content was incorporated into the conjugate to achieve 
multi-functionality and effective in vivo targeting. The in 
vitro binding studies demonstrated that the RGD targeted 
conjugate was effective for targeting the ανβ3 integrin. The 
c(RGDfK) peptide had higher binding afﬁ  nities in the DU145 
cells than in SLK cells (p < 0.03 at both 5 and 50 μM). The 
binding afﬁ  nity of polymer bound c(RGDfK) was lower than 
free c(RGDfK) (p < 0.03), which is possibly due to the steric 
effect of the polymer chains. The RGD targeted conjugate 
had higher binding afﬁ  nity to the DU145 cells as compared 
with the SLK cells (p = 0.31 at 5 μM and p < 0.01 at 50 μM), 
consistent to c(RGDfK) afﬁ  nity.
A very low dose (5.0 μM-Gd/kg) was used to avoid 
nonspeciﬁ  c tissue interactions of the conjugates for in vivo 
imaging of the ανβ3 integrin. The dose of macromolecular 
MRI contrast agents for effective tumor MR imaging are 
generally in the range of 0.03–0.1 mmol-Gd/kg. Such a high 
dose could saturate the binding to the molecular target in the 
tumor tissues and generate a strong background signal due 
to nonspeciﬁ  c tumor accumulation. However, conventional 
MR imaging does not have sufﬁ  cient sensitivity to detect 
the changes in signal intensity around the molecular targets 
with very low concentration of Gd(III) chelates. As shown 
in Figure 2, no signiﬁ  cant enhancement was observed in 
the tumors after injection of both targeted and nontargeted 
conjugates as compared with the precontrast images. Signal 
intensity in MRI is generated by the combination of longi-
tudinal (T1) and transverse (T2) relaxations of water protons. 
Gd(III) chelate increases both longitudinal (1/T1) and trans-
verse (1/T2) relaxation rates of water protons. The increase in 
the relaxation rate (1/T1) is proportional to the concentration 
of Gd(III) chelate, resulting in bright signal in MR images. 
However, the contrast agent also signiﬁ  cantly increases T2 
and T2* relaxation rate, resulting in reduction of MR signal 
intensity, which could supersede the signal increase caused 
by increasing T1 relaxation rate. Consequently, no signiﬁ  cant 
increase in signal intensity was observed in the tumor tissues 
on the MR images with conjugates at a very low dose.
T1 mapping directly measures the T1 values of tissues 
and can accurately determine the changes in the relaxation 
time caused by paramagnetic complexes. Since T1 relaxation 
rate (1/T1) is linearly correlated to the concentration of the 
contrast agents, T1 mapping has a potential to quantitatively 
determine biomarkers with targeted MRI contrast agents. 
A decrease in T1 values was observed in the periphery of 
DU145 tumor after the injection of the targeted conjugate 
on the color-coded T1 maps, while no obvious changes in the 
T1 values were found in the core of DU145 tumor, Figure 
3. No signiﬁ  cant decrease in T1 values was observed for 
the nontargeted agent in DU-145 tumor and for both conju-
gates in the SLK tumor in the T1 maps. The results indicate 
that the targeted conjugate with high binding afﬁ  nity to 
the DU145 cells resulted in signiﬁ  cant T1 reduction at the 
tumor periphery due to speciﬁ  c binding to the biomarker 
ανβ3 integrin. High T1 values inside the tumor tissue for the 
targeted conjugate might be attributed to tumor necrosis 
and inefﬁ  cient delivery of the agent to the inner tumor 
Figure 2 T 1-weighted contrast enhanced coronal MR images of mice bearing 
human prostate carcinoma DU145 (left ﬂ  ank) and Kaposi’s sarcoma SLK (right 
ﬂ  ank) xenografts before and at 8 minutes after injection of the c(RGDfK) contain-
ing PGA-cystamine-(Gd-DO3A) conjugate (A) and PGA-cystamine-(Gd-DO3A) (B).International Journal of Nanomedicine 2007:2(2) 198
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tissue (Padera et al 2004). Speciﬁ  c binding of the targeted 
conjugate to the SLK tumor tissue was trivial and nonspeciﬁ  c 
accumulation of the nontargeted conjugate in both tumors 
was minimal. Consequently, no signiﬁ  cant reduction of T1 
values was observed for the targeted conjugate with low 
binding afﬁ  nity in the SLK tumor and for the nontargeted 
conjugate in both tumors.
The RGD targeted PGA-cystamine-(Gd-DO3A) conju-
gate was effective for targeting the angiogenesis biomarker, 
ανβ3 integrin, and quantitative T1 mapping was more sensitive 
for detecting the bound targeted agent than conventional 
T1-weighted MRI. The RGD targeted PGA-cystamine-
(Gd-DO3A) was able to speciﬁ  cally deliver a large amount 
of Gd-DO3A to the target, resulting in detectable T1 shorten-
ing with T1 mapping. Since a very low dose was used, the 
nonspeciﬁ  c accumulation of the polymer conjugate in the 
solid tumor was minimized leading to reduced background 
MR signal, and allowing the detection of  T1 shortening in the 
tissue with high expression of the ανβ3 integrin. However, the 
load of Gd(III) chelates to the PGA polymer conjugate was 
still relatively low. The efﬁ  cacy of targeted paramagnetic 
polymer conjugate can be further improved for MR molecular 
imaging if the loading efﬁ  ciency of the Gd(III) chelate to the 
polymer carrier is improved. 
In conclusion, the conjugation of the RGD peptide to 
PGA-cystamine-(Gd-DO3A) maintained its binding afﬁ  nity 
to ανβ3 integrin. The targeted conjugate had a high binding 
afﬁ  nity to human prostate carcinoma DU145 cell line and 
was effective for the detection of the angiogenesis biomarker 
ανβ3 integrin in the DU145 tumor with quantitative T1 map-
ping. Targeted polymeric Gd(III) chelate conjugate with a 
biodegradable spacer can be a new paradigm for safe and 
effective probes in MR molecular imaging.
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